Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin
Randomized Open-label Phase III Study Comparing Perioperative FOLFIRI Versus Adjuvant FOLFIRI in Resectable Advanced Colorectal Cancer Failed to Oxaliplatin-containing Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Jian Xiao, MD
- Phone Number: +8613711114566
- Email: xiao_jian@139.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510655
- Recruiting
- The 6th Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Jian Xiao, MD
- Phone Number: +8613711114566
- Email: xiao_jian@139.com
-
Sub-Investigator:
- Jian Xiao, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age:18-80
- ECOG score: 0 or 1
- Histological confirmed of Colorectal Adenocarcinoma
- History of exposure to oxaliplatin
- With local recurrent or metastatic focus
- Tumor resectable confirmed by at less 3 hepatobiliary surgeon
- Informed content acquired
Exclusion Criteria:
- History of Exposure to Irinotecan
- Received surgery in recently 4 weeks or did not recover from surgery
- Other history of cancer in recent 5 years
- Fluorouracil allergy or dihydropyrimidine dehydrogenase defect
- Women with potential pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Neoadjuvant therapy arm
FOLFIRI * 6 cycles +/- radiotherapy -> surgery -> FOLFIRI * 6 cycles
|
|
|
Active Comparator: Adjuvant therapy arm
Surgery -> FOLFIRI * 12 cycles +/- radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progress Free Survival
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: 3 Years
|
3 Years
|
|
|
R0 Resection Rate
Time Frame: 6 Month
|
6 Month
|
|
|
Treatment RelatedToxicity
Time Frame: 3 Year
|
Adverse events grade that greater than 3 is considered secondary endpoint, according to the Common Terminology Criteria for Adverse Events Version 3.0.
|
3 Year
|
|
Life Quality
Time Frame: 3 Years
|
EORTC QoL Questionaires
|
3 Years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ping Lan, MD, Sixth Affiliated Hospital, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Site
- Disease Attributes
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Processes
- Neoplasms
- Colorectal Neoplasms
- Recurrence
- Neoplasm Recurrence, Local
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Fluorouracil
- Irinotecan
Other Study ID Numbers
Other Study ID Numbers
- SAH 5010 CRC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.